2020
Molecular and clinicopathologic characterization of intravenous leiomyomatosis
Ordulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Modern Pathology 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.Peer-Reviewed Original ResearchConceptsIntravenous leiomyomatosisAggressive clinical behaviorClinical behaviorArray comparative genomic hybridizationCyclin D1Uterine smooth muscle tumorsSmooth muscle tumorsSmooth muscle proliferationRecurrent chromosome alterationsCommon genetic alterationsFH immunohistochemistryClinicopathologic characterizationImmunohistochemical findingsMesenchymal tumorsMuscle tumorsBenign appearanceMuscle proliferationUterine leiomyomaGroup 1Group 3Nonneoplastic tissuesIndex scoreVascular morphologyProtein expressionComparative genomic hybridization
2014
Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers
Adeniran AJ, Hui P. Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. Expert Review Of Endocrinology & Metabolism 2014, 9: 571-577. PMID: 30736195, DOI: 10.1586/17446651.2014.951635.Peer-Reviewed Original ResearchBRAF V600E mutationPapillary thyroid carcinomaThyroid carcinomaV600E mutationPAX8/PPARγ rearrangementsSubsequent core needle biopsyUndetermined significance/atypiaFine needle aspiration cytologyBRAF V600E mutation testingLow-stage diseaseCore needle biopsyRoutine clinical practiceAggressive tumor behaviorNeedle aspiration cytologyBRAF mutation testingFine-needle aspiration specimensUndetermined significance categoryIndeterminate fine-needle aspiration cytologyNeedle aspiration specimensPredictability of malignancyCommon genetic alterationsMutation testingRET/papillary thyroid carcinomaThyroid fine-needle aspiration specimensIndependent predictors